
Jaap Kwekkeboom

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6774763/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13109-13113.	7.1	422
2	Antibodies Against Immune Checkpoint Molecules RestoreÂFunctions of Tumor-Infiltrating T Cells in HepatocellularÂCarcinomas. Gastroenterology, 2017, 153, 1107-1119.e10.	1.3	309
3	Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology, 2004, 40, 738-746.	7.3	224
4	Modulation of the cellular immune system by intravenous immunoglobulin. Trends in Immunology, 2008, 29, 608-615.	6.8	186
5	Hepatocyte-derived microRNAs as serum biomarkers of hepatic injury and rejection after liver transplantation, 2012, 18, 290-297.	2.4	177
6	Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology, 2013, 57, 183-194.	7.3	147
7	PD-L1, Galectin-9 and CD8 ⁺ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncolmmunology, 2017, 6, e1273309.	4.6	117
8	Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. Hepatology, 2012, 55, 1673-1683.	7.3	91
9	Secreted Factors of Human Liver-Derived Mesenchymal Stem Cells Promote Liver Regeneration Early After Partial Hepatectomy. Stem Cells and Development, 2012, 21, 2410-2419.	2.1	90
10	Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. Journal of Hepatology, 2019, 71, 753-762.	3.7	81
11	Tumor-infiltrating plasmacytoid dendritic cells promote immunosuppression by Tr1 cells in human liver tumors. Oncolmmunology, 2015, 4, e1008355.	4.6	78
12	Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation. Liver Transplantation, 2010, 16, 895-908.	2.4	72
13	Defining Early Human NK Cell Developmental Stages in Primary and Secondary Lymphoid Tissues. PLoS ONE, 2012, 7, e30930.	2.5	69
14	Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells. Blood, 2007, 110, 3253-3262.	1.4	68
15	Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction. Journal of Hepatology, 2016, 64, 1274-1282.	3.7	64
16	Characterization of human liver dendritic cells in liver grafts and perfusates. Liver Transplantation, 2006, 12, 384-393.	2.4	56
17	NK cells can generate from precursors in the adult human liver. European Journal of Immunology, 2011, 41, 3340-3350.	2.9	54
18	Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer. Oncolmmunology, 2018, 7, e1448332.	4.6	54

JAAP KWEKKEBOOM

#	Article	IF	CITATIONS
19	Tumor cell expression of immune inhibitory molecules and tumor-infiltrating lymphocyte count predict cancer-specific survival in pancreatic and ampullary cancer. International Journal of Cancer, 2017, 141, 572-582.	5.1	53
20	MicroRNA profiles in graft preservation solution are predictive of ischemic-type biliary lesions after liver transplantation. Journal of Hepatology, 2013, 59, 1231-1238.	3.7	52
21	Intravenous Immunoglobulin Treatment in Humans Suppresses Dendritic Cell Function via Stimulation of IL-4 and IL-13 Production. Journal of Immunology, 2014, 192, 5625-5634.	0.8	50
22	Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation. Frontiers in Immunology, 2018, 9, 389.	4.8	49
23	Cytokine gene polymorphisms and acute human liver graft rejection. Liver Transplantation, 2002, 8, 603-611.	2.4	45
24	GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells <i>ex vivo</i> . OncoImmunology, 2015, 4, e1051297.	4.6	45
25	Allosuppressive Donor CD4+CD25+ Regulatory T Cells Detach from the Graft and Circulate in Recipients after Liver Transplantation. Journal of Immunology, 2007, 178, 6066-6072.	0.8	44
26	Mobilization of hepatic mesenchymal stem cells from human liver grafts. Liver Transplantation, 2011, 17, 596-609.	2.4	44
27	Intravenous Immunoglobulins Promote Skin Allograft Acceptance by Triggering Functional Activation of CD4+Foxp3+ T cells. Transplantation, 2010, 89, 1446-1455.	1.0	43
28	Human plasmacytoid dendritic cells induce CD8 ⁺ LAGâ€3 ⁺ Foxp3 ⁺ CTLAâ€4 ⁺ regulatory T cells that suppress alloâ€reactive memory T cells. European Journal of Immunology, 2011, 41, 1663-1674.	2.9	43
29	TIGIT and PD1 Co-blockade Restores exÂvivo Functions of Human Tumor-Infiltrating CD8+ T Cells in Hepatocellular Carcinoma. Cellular and Molecular Gastroenterology and Hepatology, 2021, 12, 443-464.	4.5	43
30	Superior Immunomodulatory Effects of Intravenous Immunoglobulins on Human T-cells and Dendritic Cells: Comparison to Calcineurin Inhibitors. Transplantation, 2006, 81, 1725-1734.	1.0	42
31	GITR ligation enhances functionality of tumorâ€infiltrating T cells in hepatocellular carcinoma. International Journal of Cancer, 2019, 145, 1111-1124.	5.1	42
32	Recipient CTLA-4 +49 G/G Genotype Is Associated with Reduced Incidence of Acute Rejection After Liver Transplantation. American Journal of Transplantation, 2003, 3, 1587-1594.	4.7	40
33	Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels. Scientific Reports, 2019, 9, 10677.	3.3	37
34	Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis. British Journal of Cancer, 2020, 123, 196-206.	6.4	35
35	An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity. Cancer Immunology Research, 2021, 9, 1141-1157.	3.4	33
36	Cross-Tissue Transcriptomic Analysis of Human Secondary Lymphoid Organ-Residing ILC3s Reveals a Quiescent State in the Absence of Inflammation. Cell Reports, 2017, 21, 823-833.	6.4	32

JAAP KWEKKEBOOM

#	Article	IF	CITATIONS
37	Differences in Anti-Inflammatory Actions of Intravenous Immunoglobulin between Mice and Men: More than Meets the Eye. Frontiers in Immunology, 2015, 6, 197.	4.8	30
38	Dexamethasone transforms lipopolysaccharideâ€stimulated human blood myeloid dendritic cells into myeloid dendritic cells that prime interleukinâ€10 production in T cells. Immunology, 2008, 125, 91-100.	4.4	29
39	Early differentiation between rejection and infection in liver transplant patients by serum and biliary cytokine patterns. Transplantation, 2003, 75, 146-151.	1.0	28
40	HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis. British Journal of Cancer, 2020, 122, 1211-1218.	6.4	26
41	Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells. British Journal of Cancer, 2022, 127, 649-660.	6.4	23
42	Protective Cytomegalovirus (CMV)-Specific T-Cell Immunity Is Frequent in Kidney Transplant Patients without Serum Anti-CMV Antibodies. Frontiers in Immunology, 2017, 8, 1137.	4.8	22
43	Modulation of Dendritic Cells and Regulatory T Cells by Naturally Occurring Antibodies. Advances in Experimental Medicine and Biology, 2012, 750, 133-144.	1.6	19
44	Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection. Transplantation Reviews, 2017, 31, 78-86.	2.9	19
45	Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma. Human Pathology, 2006, 37, 332-338.	2.0	17
46	Suppression of Hepatocellular Carcinoma by Mycophenolic Acid in Experimental Models and in Patients. Transplantation, 2019, 103, 929-937.	1.0	16
47	Migration of allosensitizing donor myeloid dendritic cells into recipients after liver transplantation. Liver Transplantation, 2010, 16, 12-22.	2.4	15
48	Differential Sensitivities of Fast- and Slow-Cycling Cancer Cells to Inosine Monophosphate Dehydrogenase 2 Inhibition by Mycophenolic Acid. Molecular Medicine, 2015, 21, 792-802.	4.4	14
49	Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma. Journal of Molecular Medicine, 2019, 97, 77-88.	3.9	14
50	Donor and recipient HLA/KIR genotypes do not predict liver transplantation outcome. Transplant International, 2011, 24, 932-942.	1.6	13
51	Cancer inflammation and inflammatory biomarkers: can neutrophil, lymphocyte, and platelet counts represent the complexity of the immune system?. Transplant International, 2014, 27, 28-31.	1.6	13
52	Cytomegalovirus-Induced Expression of CD244 after Liver Transplantation Is Associated with CD8+ T Cell Hyporesponsiveness to Alloantigen. Journal of Immunology, 2015, 195, 1838-1848.	0.8	13
53	T-cell inhibitory capacity of hyperimmunoglobulins is influenced by the production process. International Immunopharmacology, 2014, 19, 142-144.	3.8	12
54	Characterization of Antigen-Presenting Cell Subsets in Human Liver-Draining Lymph Nodes. Frontiers in Immunology, 2019, 10, 441.	4.8	12

JAAP KWEKKEBOOM

#	Article	IF	CITATIONS
55	Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers. British Journal of Cancer, 2021, , .	6.4	12
56	FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells. , 2020, 8, e000816.		11
57	Detection of oncogenic mutations in paired circulating tumor DNA and circulating tumor cells in patients with hepatocellular carcinoma. Translational Oncology, 2021, 14, 101073.	3.7	10
58	CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation. Transplantation, 2002, 73, 1666-1672.	1.0	9
59	Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma. Carcinogenesis, 2019, 40, 155-163.	2.8	9
60	Activated CD4+ T Cells and Highly Differentiated Alloreactive CD4+ T Cells Distinguish Operationally Tolerant Liver Transplantation Recipients. Liver Transplantation, 2022, 28, 98-112.	2.4	8
61	Detailed Kinetics of the Direct Allo-Response in Human Liver Transplant Recipients: New Insights from an Optimized Assay. PLoS ONE, 2010, 5, e14452.	2.5	7
62	No evidence for involvement of donor NK cells in liver transplant tolerance. Transplant Immunology, 2011, 24, 138-139.	1.2	7
63	HLA matching and rabbit antithymocyte globulin as induction therapy to avoid multiple forms of rejection after a third liver transplantation. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101539.	1.5	5
64	Immunosuppressive drug withdrawal late after liver transplantation improves the lipid profile and reduces infections. European Journal of Gastroenterology and Hepatology, 2019, 31, 1444-1451.	1.6	5
65	Blockade of intragraft IL-2 receptor-α by basiliximab is insufficient to prevent activation of liver graft infiltrating cells. Transplant Immunology, 2003, 11, 1-5.	1.2	4
66	Expression of Cancer Testis Antigens in Tumor-Adjacent Normal Liver Is Associated with Post-Resection Recurrence of Hepatocellular Carcinoma. Cancers, 2021, 13, 2499.	3.7	4
67	Cancer Cell B7-H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer. Frontiers in Oncology, 2021, 11, 615691.	2.8	3
68	Strain-specific in vitro cytokine production profiles do not predict rat liver allograft survival. Transplant International, 2004, 17, 779-786.	1.6	2
69	Prevention of immunoglobulin G immobilization eliminates artifactual stimulation of dendritic cell maturation by intravenous immunoglobulin inÂvitro. Translational Research, 2014, 163, 557-564.	5.0	2
70	Camrelizumab—targeting a novel PD-1 epitope to treat hepatocellular carcinoma. Annals of Translational Medicine, 2020, 8, 1614-1614.	1.7	2
71	Rotterdam: Main port for organ transplantation research in the Netherlands. Transplant Immunology, 2014, 31, 200-206.	1.2	1
72	Current Tolerance-Associated Peripheral Blood Gene Expression Profiles After Liver Transplantation Are Influenced by Immunosuppressive Drugs and Prior Cytomegalovirus Infection. Frontiers in Immunology, 2021, 12, 738837.	4.8	1